Brain-Derived Neurotrophic Factor and Obesity in WAGR Syndrome Aug 28, 2008
The extent of each deletion was determined with the use of oligonucleotide comparative genomic hybridization. Results Deletions of chromosome 11p in the patients studied ranged from 1. (New England Journal of Medicine)
Bioniche Presents Pre-Clinical Research at Two International Conferences May 24, 2008
The presentation, entitled, "Mycobacteria-derived immunopotentiating molecules and their application in vaccine development", was made by Dr. Nigel C. Phillips, Chief Scientific Officer of Bioniche Life Sciences Inc. Dr. Phillips discussed the development pathway from MCC to the Company's synthetic oligonucleotides, and reviewed their immune stimulatory and immune adjuvant activity. "The data presented clearly demonstrate that the Company's proprietary, synthetic, non-CpG containing... (PR Newswire)
BioMs Medical to present at TIDES(R) Conference May 13, 2008
Toronto Stock Exchange Symbol: MS EDMONTON, May 13 /CNW/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Dr. Mark Krantz, Vice President Scientific Affairs, BioMS Medical, will present at the TIDES(R) - Oligonucleotide and Peptide Technology and Product Development Conference in Las Vegas. About TIDES(R) Conference ------------------------- TIDES(R) is the only forum that covers manufacturing, formulation, delivery, process... (Canada Newswire)
Scientists identify genomic 'fingerprint' for alcohol-induced heart failure May 5, 2008
They analyzed an array containing 1,143 heart-specific oligonucleotide probes that is normally used to screen ribonucleic acid (RNA) samples from transplant recipients and organ donors with alcohol-related heart failure. The researchers then compared messenger RNA (mRNA) from the hearts of persons with alcohol-related heart failure with mRNA from the hearts of persons who did not engage in excessive drinking. (EurekAlert!)
Genetic Diagnostics Expert, Dr. Kavita Reddy, Joins CombiMatrix as Laboratory Director Feb 15, 2008
The technologies we have developed include a platform technology to rapidly produce customizable, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. (Primezone Releases)
Duchenne's Muscular Dystrophy Advance? Dec 28, 2007
In the test tube, a compound called an antisense oligonucleotide partially corrects this genetic misreading. It seems to work in animals. (CBS News)
Local Dystrophin Restoration with PRO051 Dec 27, 2007
NEJM -- Local Dystrophin Restoration with Antisense Oligonucleotide PRO051 ... Local Dystrophin Restoration with Antisense Oligonucleotide PRO051 ... We explored the safety, adverse-event profile, and local dystrophin-restoring effect of a single, intramuscular dose of an antisense oligonucleotide, PRO051, in patients with this disease. (New England Journal of Medicine)
A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols Sep 5, 2007
The method, called the oligonucleotide ligation assay (OLA), will be useful for identifying individuals with disease-related mutations and other genetic variants. It was contributed by Dr. Stuart Macdonald from the University of Kansas (). (EurekAlert!)
Mouse genome will help identify causes of environmental disease Jul 30, 2007
The technology used, the oligonucleotide array, was also used to discover common DNA variation in the human genome. The arrays looked at about 1. (EurekAlert!)
ADA Conference Presentations Highlight Isis' Metabolic Disease Program Research Activities Jun 25, 2007
"In our pipeline we have ISIS 113715, a novel insulin sensitizer targeting PTP-1B which may also promote weight loss. In addition, we have ISIS 325568, targeting glucagon receptor, which inhibits glucagon action in the liver and has additional potentially disease-modifying effects in the pancreas. And we have ISIS 377131, targeting glucocorticoid receptor selectively in liver and fat, which has multiple metabolic effects in addition to lowering glucose such as anti-obesity and lipid-lowering... (PR Newswire)
Who is Robert Cooksey? Jun 22, 2007
In the two papers, researchers identified strains from more than 90 countries using spacer oligonucleotide typing, a new and faster method that uses PCR amplification to detect M. tuberculosis isolates and identify related strains in a much shorter time period than previous techniques. The two studies built on each other to describe TB genotype diversity. (The Scientist)
Tekmira Pharmaceuticals Provides Operational Update at AGM Jun 20, 2007
Tekmira's internal development is focused on novel oligonucleotide drugs. Oligonucleotides are short sequences of deoxyribonucleic acid, or DNA, and ribonucleic acid, or RNA. DNA and RNA are the molecules that determine the genetic building plan of any organism ... Oligonucleotide drugs can treat disease by either stimulating the body's immune system or by switching off genes that produce disease-causing proteins. (CCNMatthews Press Releases)
CoDa Therapeutics Secures $10.0 Million in Additional Series A Financing Feb 22, 2007
"This is a very exciting opportunity, for investors and patients alike, and we believe that CoDa's first clinical indication, enhancement of healing following photorefractive keratectomy (PRK), is an ideal initial ocular indication to demonstrate the ability of its lead drug candidate, Nexagon(TM), to increase the rate of re-epithelialization while potentially reducing inflammation and scarring." About Nexagon(TM) CoDa's technology includes the company's lead drug product Nexagon(TM), a patented... (PR Newswire)
New Technique Assesses Effects Of Multiple Copies Of Genes On Disease Risk Feb 1, 2007
Nimblegen's technique for rapid analysis is known as oligonucleotide array comparative genomic hybridization. "The copy number variants we describe in this paper are numerous and fairly large they vary in length between two thousand and two million DNA base pairs," Graubert says. (Science Daily)
New 'GreeneChip' identifies multiple pathogens rapidly and accurately Dec 7, 2006
ARTICLE: Panmicrobial oligonucleotide array for diagnosis of infectious diseases by G Palacios et al. Emerging Infectious Diseases (2006). This study was conducted by scientists at Columbia University; Stanford University; the University of Chicago; the Institute of Enzymology, Budapest, Hungary; the Public Health Agency of Canada, Winnipeg, Canada; the U.S. Centers for Disease Control and Prevention; the U.S. Army Medical Research Institute of Infectious Diseases; the National Institutes of... (EurekAlert!)
Structural variations common in human genome Nov 28, 2006
D. Komura et al. "Genome-wide detection of human copy number variations using high density DNA oligonucleotide arrays," Genome Research, published online ahead of print Nov. 22, 2006. H. Fiegler et al. "Accurate and reliable high-throughput detection of copy number variation in the human genome."Genome Research, published online ahead of print Nov. 22, 2006. (The Scientist)
Mouse DNA to aid biomedical research Oct 26, 2006
The project used the same high-density oligonucleotide array technology that was used to discover common DNA variation in the human genome. "Perlegen Sciences was excited to perform this scientific work, because it promised to provide an extremely valuable resource. We believe the data will generate a lot of knowledge about complex genetic traits," said Kelly Frazer, Vice President of Genomics at Perlegen Sciences, Inc.. (EurekAlert!)
Promising therapy for ALS delivers antisense drug directly to nervous system Jul 27, 2006
D., UCSD Professor of Medicine, Neurosciences and Cellular and Molecular Medicine and member of the Ludwig Institute for Cancer Research, shows that therapeutic molecules known as antisense oligonucleotides can be delivered to the brain and spinal cord through the cerebrospinal fluid (CSF) at doses shown to slow the progression of ALS in rats ... A small catheter is then implanted into the area surrounding the spinal cord, in order to pump antisense oligonucleotide drugs directly into the... (EurekAlert!)
Large-scale cross-platform study of research microarrays uncovers high concordance across platforms Jul 3, 2006
In Kuo's study, gene expression measurements were obtained from 10 different microarray platforms (Affymetrix, Applied Biosystems, Agilent Technologies, Compugen, GE Healthcare, Mergen, MWG BioTech, Operon, academic cDNA and an academic long oligonucleotide array) and two different QRT-PCR approaches (Applied Biosystems TaqMan Assays and Roche Diagnostics Universal Probe Library). It has been an emphasized goal during this effort to develop a sound and consistent framework for cross-platform... (EurekAlert!)
Proxy Resolutions for Genta Incorporated Approved at Annual Shareholders Meeting Jun 17, 2006
The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. (PR Newswire)
Ribomed Biotechnologoies awarded first patent Jun 8, 2006
In addition to this patent, titled "Molecular Detection Systems Utilizing Reiteraive Oligonucleotide Synthesis" (Patent # US 7,045,319 B2), eight other U.S. patents involving its detection process are waiting to be cleared by the patent office. Patents applications also have been filed in Europe, Japan and Canada. (Phoenix Business Journal, AZ)
Lorus announces presentation of data from four clinical trials with three different drugs at the 2006 American Society of Clinical Oncology (ASCO) Meeting Jun 1, 2006
Four abstracts were accepted for presentation and/or publication in the meeting abstract book: - "A phase III trial of Virulizin(R) plus gemcitabine vs. gemcitabine alone in pancreatic cancer: Results of subgroup analysis" will be presented on Saturday, June 3rd, between 8:00am and noon (Abstract No: 4116, Poster Number: F10) - "A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML)" will... (Canada Newswire)
INEX Releases First Quarter 2006 Operating Results May 4, 2006
Under agreements with Protiva, INEX believes it has certain rights to obtain a fully paid-up, exclusive license from Protiva for certain oligonucleotide technology. In its statement of claim, Protiva is asking for a declaration that INEX has no claim over the disputed technology. (PR Newswire)
